EVAX
Evaxion A/S American Depositary ShareEVAX
EVAX
About: Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
Employees: 46
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
267% more capital invested
Capital invested by funds: $682K [Q4 2024] → $2.5M (+$1.82M) [Q1 2025]
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 10 [Q4 2024] → 10 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
1.02% less ownership
Funds ownership: 1.45% [Q4 2024] → 0.43% (-1.02%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for EVAX.
Financial journalist opinion
Based on 3 articles about EVAX published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.
Neutral
GlobeNewsWire
2 weeks ago
Evaxion finalizes agreement with EIB to convert debt into equity
COPENHAGEN, Denmark, July 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has finalized its agreement with the European Investment Bank (EIB) to convert debt into equity.
Neutral
GlobeNewsWire
4 weeks ago
Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio
COPENHAGEN, Denmark, July 1, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces several key executive management changes to optimize value from its proprietary AI-Immunology™ platform and pipeline.
Neutral
GlobeNewsWire
1 month ago
Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus
COPENHAGEN, Denmark, June 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, initiates work to develop a new preventive vaccine against Group A Streptococcus (GAS), a bacteria causing hundreds of millions of infections globally each year. Infection carries the risk of several complications including life threatening conditions like rheumatic heart disease and necrotizing fasciitis (“flesh eating bacteria”) and less severe yet serious diseases like strep throat and scarlet fever.
Neutral
GlobeNewsWire
1 month ago
Evaxion receives grant funding to design new polio vaccine
COPENHAGEN, Denmark, June 3, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives funding support from the Gates Foundation to help the world eradicate polio (poliomyelitis) by exploring design options for a new and unique vaccine.
Neutral
Seeking Alpha
2 months ago
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025 8:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to the Evaxion First Quarter 2025 Conference Call and Webcast.
Neutral
GlobeNewsWire
2 months ago
Evaxion announces business update and first quarter 2025 financial results
COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial results.
Positive
Seeking Alpha
2 months ago
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025
Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily backloaded, provides considerable validation of Evaxion's value. A potential option exercise by MSD expected later this year would bring in up to $10M. EVAX guides a cash runway into mid-2026, which could be extended into 2027 if MSD exercises options for both partnered candidates (not accounting for potential further business developments).
Neutral
GlobeNewsWire
2 months ago
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on Tuesday, May 27, 2025, before opening of the Nasdaq CM.
Neutral
GlobeNewsWire
2 months ago
Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has dosed the first patient in its one-year extension of the ongoing phase 2 trial with its lead asset EVX-01. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
Charts implemented using Lightweight Charts™